ZA200309004B - Heterocyclylocy-, -thioxy- and -aminobenzazole derivatives as 5-hydroxytryptamine-6 ligands. - Google Patents
Heterocyclylocy-, -thioxy- and -aminobenzazole derivatives as 5-hydroxytryptamine-6 ligands. Download PDFInfo
- Publication number
- ZA200309004B ZA200309004B ZA200309004A ZA200309004A ZA200309004B ZA 200309004 B ZA200309004 B ZA 200309004B ZA 200309004 A ZA200309004 A ZA 200309004A ZA 200309004 A ZA200309004 A ZA 200309004A ZA 200309004 B ZA200309004 B ZA 200309004B
- Authority
- ZA
- South Africa
- Prior art keywords
- optionally substituted
- compound
- formula
- aryl
- group
- Prior art date
Links
- 239000003446 ligand Substances 0.000 title description 4
- 150000001875 compounds Chemical class 0.000 claims description 75
- 125000001072 heteroaryl group Chemical group 0.000 claims description 44
- 125000003118 aryl group Chemical group 0.000 claims description 36
- -1 (2-fluorophenyl) sulfonyl Chemical group 0.000 claims description 26
- 125000000217 alkyl group Chemical group 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 21
- 108091005435 5-HT6 receptors Proteins 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 14
- 150000003839 salts Chemical class 0.000 claims description 14
- 125000001424 substituent group Chemical group 0.000 claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
- 229910052736 halogen Inorganic materials 0.000 claims description 11
- 150000002367 halogens Chemical class 0.000 claims description 11
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 11
- 125000006239 protecting group Chemical group 0.000 claims description 9
- 125000003342 alkenyl group Chemical group 0.000 claims description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 6
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 5
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims description 5
- 210000003169 central nervous system Anatomy 0.000 claims description 5
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 claims description 4
- 208000019901 Anxiety disease Diseases 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N N-phenyl amine Natural products NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 4
- 239000002168 alkylating agent Substances 0.000 claims description 4
- 229940100198 alkylating agent Drugs 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 4
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 3
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims description 3
- 208000019430 Motor disease Diseases 0.000 claims description 3
- 230000002152 alkylating effect Effects 0.000 claims description 3
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims description 3
- 208000010877 cognitive disease Diseases 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 201000000980 schizophrenia Diseases 0.000 claims description 3
- VBKVAQLWDIGFGA-UHFFFAOYSA-N 1-(benzenesulfonyl)-4-pyrrolidin-3-yloxyindazole Chemical compound N1=CC2=C(OC3CNCC3)C=CC=C2N1S(=O)(=O)C1=CC=CC=C1 VBKVAQLWDIGFGA-UHFFFAOYSA-N 0.000 claims description 2
- ZVUUWBSMLUMOGV-UHFFFAOYSA-N 1-(benzenesulfonyl)-4-pyrrolidin-3-yloxyindole Chemical compound C1=CC2=C(OC3CNCC3)C=CC=C2N1S(=O)(=O)C1=CC=CC=C1 ZVUUWBSMLUMOGV-UHFFFAOYSA-N 0.000 claims description 2
- FLCVBXYHHWCZCT-UHFFFAOYSA-N 1-(benzenesulfonyl)-5-pyrrolidin-3-yloxyindole Chemical compound C1=CC2=CC(OC3CNCC3)=CC=C2N1S(=O)(=O)C1=CC=CC=C1 FLCVBXYHHWCZCT-UHFFFAOYSA-N 0.000 claims description 2
- BMNCHGJAFIZQRO-UHFFFAOYSA-N 1-(benzenesulfonyl)-6-pyrrolidin-3-yloxyindazole Chemical compound N1=CC2=CC=C(OC3CNCC3)C=C2N1S(=O)(=O)C1=CC=CC=C1 BMNCHGJAFIZQRO-UHFFFAOYSA-N 0.000 claims description 2
- PWUVOBKUMYOQCG-UHFFFAOYSA-N 1-(benzenesulfonyl)-6-pyrrolidin-3-yloxyindole Chemical compound C1=CC2=CC=C(OC3CNCC3)C=C2N1S(=O)(=O)C1=CC=CC=C1 PWUVOBKUMYOQCG-UHFFFAOYSA-N 0.000 claims description 2
- UVIJEIXEAFHLGF-UHFFFAOYSA-N 1-naphthalen-1-ylsulfonyl-4-pyrrolidin-3-yloxyindazole Chemical compound C=1C=CC2=CC=CC=C2C=1S(=O)(=O)N(C1=CC=C2)N=CC1=C2OC1CCNC1 UVIJEIXEAFHLGF-UHFFFAOYSA-N 0.000 claims description 2
- GYZWOJSXDVKVLU-UHFFFAOYSA-N 1-naphthalen-1-ylsulfonyl-4-pyrrolidin-3-yloxyindole Chemical compound C=1C=CC2=CC=CC=C2C=1S(=O)(=O)N(C1=CC=C2)C=CC1=C2OC1CCNC1 GYZWOJSXDVKVLU-UHFFFAOYSA-N 0.000 claims description 2
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 claims description 2
- METKIMKYRPQLGS-UHFFFAOYSA-N atenolol Chemical compound CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-UHFFFAOYSA-N 0.000 claims description 2
- 150000007514 bases Chemical class 0.000 claims description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N benzopyrrole Natural products C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims description 2
- 230000002252 carbamoylating effect Effects 0.000 claims description 2
- 239000000376 reactant Substances 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims 9
- 241000124008 Mammalia Species 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 125000003107 substituted aryl group Chemical group 0.000 claims 2
- YIYCKAKUJYOQCA-UHFFFAOYSA-N 1-(5-chloro-1,3-dimethylpyrazol-4-yl)sulfonyl-4-pyrrolidin-3-yloxyindole Chemical compound CC1=NN(C)C(Cl)=C1S(=O)(=O)N1C2=CC=CC(OC3CNCC3)=C2C=C1 YIYCKAKUJYOQCA-UHFFFAOYSA-N 0.000 claims 1
- DQSOYFKETVAYGJ-UHFFFAOYSA-N 1-(5-chlorothiophen-2-yl)sulfonyl-4-piperidin-3-yloxyindazole Chemical compound S1C(Cl)=CC=C1S(=O)(=O)N1C2=CC=CC(OC3CNCCC3)=C2C=N1 DQSOYFKETVAYGJ-UHFFFAOYSA-N 0.000 claims 1
- ZRXIUHBGIMANHJ-UHFFFAOYSA-N 1-naphthalen-1-ylsulfonyl-4-piperidin-3-yloxyindazole Chemical compound C=1C=CC2=CC=CC=C2C=1S(=O)(=O)N(C1=CC=C2)N=CC1=C2OC1CCCNC1 ZRXIUHBGIMANHJ-UHFFFAOYSA-N 0.000 claims 1
- HXDJBEDXDXHWGR-UHFFFAOYSA-N 1-naphthalen-1-ylsulfonyl-4-piperidin-3-yloxyindole Chemical compound C=1C=CC2=CC=CC=C2C=1S(=O)(=O)N(C1=CC=C2)C=CC1=C2OC1CCCNC1 HXDJBEDXDXHWGR-UHFFFAOYSA-N 0.000 claims 1
- IQVAJKDHTVLLID-UHFFFAOYSA-N 1-naphthalen-1-ylsulfonyl-4-piperidin-4-yloxyindole Chemical compound C=1C=CC2=CC=CC=C2C=1S(=O)(=O)N(C1=CC=C2)C=CC1=C2OC1CCNCC1 IQVAJKDHTVLLID-UHFFFAOYSA-N 0.000 claims 1
- PBWZPMOOKRLPMG-UHFFFAOYSA-N 4-pyrrolidin-3-yloxy-1-thiophen-2-ylsulfonylindole Chemical compound C1=CC2=C(OC3CNCC3)C=CC=C2N1S(=O)(=O)C1=CC=CS1 PBWZPMOOKRLPMG-UHFFFAOYSA-N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 claims 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 claims 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 description 36
- 125000000753 cycloalkyl group Chemical group 0.000 description 12
- 125000000304 alkynyl group Chemical group 0.000 description 8
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 8
- 238000010586 diagram Methods 0.000 description 7
- 125000005843 halogen group Chemical group 0.000 description 7
- 125000003545 alkoxy group Chemical group 0.000 description 6
- 208000015114 central nervous system disease Diseases 0.000 description 6
- 238000010511 deprotection reaction Methods 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 230000006103 sulfonylation Effects 0.000 description 4
- 238000005694 sulfonylation reaction Methods 0.000 description 4
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 125000005844 heterocyclyloxy group Chemical group 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 229940076279 serotonin Drugs 0.000 description 3
- RMVRSNDYEFQCLF-UHFFFAOYSA-N thiophenol Chemical compound SC1=CC=CC=C1 RMVRSNDYEFQCLF-UHFFFAOYSA-N 0.000 description 3
- IHWDSEPNZDYMNF-UHFFFAOYSA-N 1H-indol-2-amine Chemical compound C1=CC=C2NC(N)=CC2=C1 IHWDSEPNZDYMNF-UHFFFAOYSA-N 0.000 description 2
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 2
- 125000004414 alkyl thio group Chemical group 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 2
- 125000001589 carboacyl group Chemical group 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
- 125000004438 haloalkoxy group Chemical group 0.000 description 2
- 125000001188 haloalkyl group Chemical group 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 210000001577 neostriatum Anatomy 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- 210000001009 nucleus accumben Anatomy 0.000 description 2
- 210000001010 olfactory tubercle Anatomy 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- JHHZLHWJQPUNKB-UHFFFAOYSA-N pyrrolidin-3-ol Chemical compound OC1CCNC1 JHHZLHWJQPUNKB-UHFFFAOYSA-N 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- JYLPBMFOHXCZFD-UHFFFAOYSA-N 1-(benzenesulfonyl)-4-piperidin-3-yloxyindole Chemical compound C1=CC2=C(OC3CNCCC3)C=CC=C2N1S(=O)(=O)C1=CC=CC=C1 JYLPBMFOHXCZFD-UHFFFAOYSA-N 0.000 description 1
- FADGQPUGRQZZSE-UHFFFAOYSA-N 1-(benzenesulfonyl)-4-piperidin-4-yloxyindole Chemical compound C1=CC2=C(OC3CCNCC3)C=CC=C2N1S(=O)(=O)C1=CC=CC=C1 FADGQPUGRQZZSE-UHFFFAOYSA-N 0.000 description 1
- OXDCIQYYQWBBMC-UHFFFAOYSA-N 1-(benzenesulfonyl)-5-pyrrolidin-3-yloxyindazole Chemical compound N1=CC2=CC(OC3CNCC3)=CC=C2N1S(=O)(=O)C1=CC=CC=C1 OXDCIQYYQWBBMC-UHFFFAOYSA-N 0.000 description 1
- AUSRRRUBMHIEJD-UHFFFAOYSA-N 1-phenoxypyrrolidine Chemical compound C1CCCN1OC1=CC=CC=C1 AUSRRRUBMHIEJD-UHFFFAOYSA-N 0.000 description 1
- JHFAEUICJHBVHB-UHFFFAOYSA-N 1h-indol-2-ol Chemical compound C1=CC=C2NC(O)=CC2=C1 JHFAEUICJHBVHB-UHFFFAOYSA-N 0.000 description 1
- FAUNIENDCMKSHE-UHFFFAOYSA-N 2-(nitromethyl)phenol Chemical compound OC1=CC=CC=C1C[N+]([O-])=O FAUNIENDCMKSHE-UHFFFAOYSA-N 0.000 description 1
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 description 1
- HCGYMSSYSAKGPK-UHFFFAOYSA-N 2-nitro-1h-indole Chemical compound C1=CC=C2NC([N+](=O)[O-])=CC2=C1 HCGYMSSYSAKGPK-UHFFFAOYSA-N 0.000 description 1
- OZGLUMWIQJPWHX-UHFFFAOYSA-N 2-pyrrolidin-1-yloxy-1h-indole Chemical compound C1CCCN1OC1=CC2=CC=CC=C2N1 OZGLUMWIQJPWHX-UHFFFAOYSA-N 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 description 1
- ALIGZGDZIDZFSB-UHFFFAOYSA-N 3-pyrrolidin-1-yloxy-1h-indazole Chemical compound C1CCCN1OC1=NNC2=CC=CC=C12 ALIGZGDZIDZFSB-UHFFFAOYSA-N 0.000 description 1
- 102100036321 5-hydroxytryptamine receptor 2A Human genes 0.000 description 1
- 101710138091 5-hydroxytryptamine receptor 2A Proteins 0.000 description 1
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 208000032841 Bulimia Diseases 0.000 description 1
- 206010006550 Bulimia nervosa Diseases 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- 208000019454 Feeding and Eating disease Diseases 0.000 description 1
- 102000014630 G protein-coupled serotonin receptor activity proteins Human genes 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 1
- 206010033664 Panic attack Diseases 0.000 description 1
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 1
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 1
- 230000009102 absorption Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 210000004727 amygdala Anatomy 0.000 description 1
- SMWDFEZZVXVKRB-UHFFFAOYSA-N anhydrous quinoline Natural products N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 150000001502 aryl halides Chemical class 0.000 description 1
- 125000003943 azolyl group Chemical group 0.000 description 1
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 125000003310 benzodiazepinyl group Chemical class N1N=C(C=CC2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 210000001947 dentate gyrus Anatomy 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 229960004756 ethanol Drugs 0.000 description 1
- 230000004634 feeding behavior Effects 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- OWFXIOWLTKNBAP-UHFFFAOYSA-N isoamyl nitrite Chemical compound CC(C)CCON=O OWFXIOWLTKNBAP-UHFFFAOYSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000006993 memory improvement Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 230000037023 motor activity Effects 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- WATRIWBCBLIULO-UHFFFAOYSA-N n-pyrrolidin-1-yl-1h-indol-2-amine Chemical compound C1CCCN1NC1=CC2=CC=CC=C2N1 WATRIWBCBLIULO-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 230000000955 neuroendocrine Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 208000019906 panic disease Diseases 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 229940124606 potential therapeutic agent Drugs 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- QGKLPGKXAVVPOJ-UHFFFAOYSA-N pyrrolidin-3-one Chemical compound O=C1CCNC1 QGKLPGKXAVVPOJ-UHFFFAOYSA-N 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000000858 thiocyanato group Chemical group *SC#N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Anesthesiology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28564301P | 2001-04-20 | 2001-04-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200309004B true ZA200309004B (en) | 2005-02-21 |
Family
ID=23095111
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200309004A ZA200309004B (en) | 2001-04-20 | 2003-11-19 | Heterocyclylocy-, -thioxy- and -aminobenzazole derivatives as 5-hydroxytryptamine-6 ligands. |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US6815456B2 (es) |
| EP (1) | EP1385842A1 (es) |
| JP (1) | JP4323810B2 (es) |
| KR (1) | KR20030088508A (es) |
| CN (1) | CN1293072C (es) |
| AR (1) | AR035235A1 (es) |
| BR (1) | BR0209056A (es) |
| CA (1) | CA2444095A1 (es) |
| EA (1) | EA200301142A1 (es) |
| EC (2) | ECSP034810A (es) |
| HU (1) | HUP0303958A2 (es) |
| IL (1) | IL158445A0 (es) |
| MX (1) | MXPA03009476A (es) |
| NO (1) | NO20034648L (es) |
| PL (1) | PL367297A1 (es) |
| WO (1) | WO2002085892A1 (es) |
| ZA (1) | ZA200309004B (es) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA03011244A (es) * | 2001-06-07 | 2004-02-27 | Hoffmann La Roche | Nuevos derivados de indol con afinidad por el receptor 5-ht6. |
| JP2005518097A (ja) * | 2002-02-13 | 2005-06-16 | コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ | 集積半導体光学装置並びにこのような装置を製造する方法及び装置 |
| JP4390698B2 (ja) * | 2002-06-05 | 2009-12-24 | エフ．ホフマン−ラ ロシュ アーゲー | Ｃｎｓ障害の処置のための５−ｈｔ６レセプターモジュレーターとしての１−スルホニル−４−アミノアルコキシインドール誘導体 |
| BRPI0406761A (pt) | 2003-01-14 | 2005-12-20 | Arena Pharm Inc | Derivados de arila e heteroarila 1,2,3-trissubstituìdos como moduladores do metabolismo e a profilaxia e tratamento de distúrbios relacionados a estes tais como diabetes e hiper-glicemia |
| KR20050101551A (ko) * | 2003-02-14 | 2005-10-24 | 와이어쓰 | 5-하이드록시트립타민-6 리간드로서의헤테로사이클릴-3-설포닐인다졸 |
| SE0302760D0 (sv) * | 2003-10-20 | 2003-10-20 | Biovitrum Ab | New compounds |
| DE102004010132A1 (de) * | 2004-02-27 | 2005-09-15 | Merck Patent Gmbh | Piperidinderivate |
| GB0422263D0 (en) * | 2004-10-07 | 2004-11-10 | Glaxo Group Ltd | Novel compounds |
| ATE417830T1 (de) * | 2004-11-02 | 2009-01-15 | Pfizer | Sulfonylbenzimidazolderivate |
| DOP2006000010A (es) * | 2005-01-10 | 2006-07-31 | Arena Pharm Inc | Procedimiento para preparar eteres aromáticos |
| CA2594487A1 (en) * | 2005-01-19 | 2006-07-27 | Matthias Heinrich Nettekoven | 5-aminoindole derivatives |
| AU2006291414A1 (en) * | 2005-08-15 | 2007-03-22 | Wyeth | Azinyl-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6 ligands |
| CN101282938A (zh) * | 2005-08-15 | 2008-10-08 | 惠氏公司 | 作为5-羟色胺-6配体的经取代3-磺酰基吲唑衍生物 |
| JP2009532471A (ja) * | 2006-04-05 | 2009-09-10 | ワイス | ５−ヒドロキシトリプタミン−６リガンドとしてのスルホニル−３−ヘテロシクリルインダゾール誘導体 |
| WO2007120596A1 (en) * | 2006-04-12 | 2007-10-25 | Wyeth | DIHYDRO[1,4]DIOXINO[2,3-e]INDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS |
| MX2008015329A (es) * | 2006-06-01 | 2008-12-12 | Wyeth Corp | Derivados 1-sulfonilindazolilamina y -amida como ligandos de 5-hidroxitriptamina-6. |
| US20090023925A1 (en) * | 2007-06-28 | 2009-01-22 | Wyeth | N'-(2-halobenzylidene)sulfonylhydrazides as intermediates in the manufacture of arylsulfonylindazoles |
| WO2009034581A1 (en) * | 2007-09-11 | 2009-03-19 | Suven Life Sciences Limited | Substituted indolyl compounds and their use as 5-ht6 ligands |
| JP2013526542A (ja) | 2010-05-12 | 2013-06-24 | アッヴィ・インコーポレイテッド | キナーゼのインダゾール阻害薬 |
| AU2011305525B2 (en) | 2010-09-22 | 2016-08-18 | Arena Pharmaceuticals, Inc. | Modulators of the GPR119 receptor and the treatment of disorders related thereto |
| EA022623B1 (ru) | 2010-10-06 | 2016-02-29 | ГЛАКСОСМИТКЛАЙН ЭлЭлСи | Производные бензимидазола в качестве ингибиторов pi3-киназ |
| EP3083588B1 (en) | 2013-12-20 | 2020-12-09 | Sunshine Lake Pharma Co., Ltd. | Aromatic heterocyclic compounds and their application in pharmaceuticals |
| AU2015286049B2 (en) * | 2014-07-08 | 2018-03-01 | Sunshine Lake Pharma Co., Ltd. | Aromatic heterocyclic derivatives and pharmaceutical applications thereof |
| AU2016205361C1 (en) | 2015-01-06 | 2021-04-08 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the S1P1 receptor |
| IL285890B (en) | 2015-06-22 | 2022-07-01 | Arena Pharm Inc | Slate-free crystal of the arginine salt of (Ar)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-4,3,2,1-tetrahydro-cyclopent[b]indole-3-yl ) acetic acid |
| US11534424B2 (en) | 2017-02-16 | 2022-12-27 | Arena Pharmaceuticals, Inc. | Compounds and methods for treatment of primary biliary cholangitis |
| CN111233736B (zh) * | 2020-03-16 | 2021-07-16 | 东莞市东阳光新药研发有限公司 | 芳杂环类衍生物的盐及其用途 |
| WO2024032530A1 (zh) * | 2022-08-11 | 2024-02-15 | 江苏恩华药业股份有限公司 | 芳杂环并环己烷基氨基烷基哌啶衍生物、制备方法及其用途 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3835291A1 (de) | 1988-04-19 | 1989-11-02 | Bayer Ag | 1,3-disubstituierte pyrrolidine |
| GB9103862D0 (en) * | 1991-02-25 | 1991-04-10 | Glaxo Group Ltd | Chemical compounds |
| US5578716A (en) * | 1993-12-01 | 1996-11-26 | Mcgill University | DNA methyltransferase antisense oligonucleotides |
| JPH0940646A (ja) | 1995-07-27 | 1997-02-10 | Yamanouchi Pharmaceut Co Ltd | ベンゼン縮合環誘導体又はその塩 |
| AU7526798A (en) * | 1997-04-18 | 1998-11-27 | Smithkline Beecham Plc | Acetamide and urea derivatives, process for their preparation and their use in the treatment of cns disorders |
| US6100291A (en) | 1998-03-16 | 2000-08-08 | Allelix Biopharmaceuticals Inc. | Pyrrolidine-indole compounds having 5-HT6 affinity |
| AU5570900A (en) | 1999-07-01 | 2001-01-22 | Sankyo Company Limited | Indoline or tetrahydroquinoline derivatives |
| CA2378047A1 (en) * | 1999-07-15 | 2001-01-25 | Methvin Isaac | Heterocyclic compounds for the treatment of migraine |
| EA200300717A1 (ru) * | 2000-12-22 | 2003-12-25 | Уайт | Гетероциклилиндазольные и -азаиндазольные соединения в качестве 5-гидрокситриптамин-6-лигандов |
| TW593278B (en) * | 2001-01-23 | 2004-06-21 | Wyeth Corp | 1-aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands |
| TW200401641A (en) * | 2002-07-18 | 2004-02-01 | Wyeth Corp | 1-Heterocyclylalkyl-3-sulfonylindole or-indazole derivatives as 5-hydroxytryptamine-6 ligands |
| KR20050101551A (ko) * | 2003-02-14 | 2005-10-24 | 와이어쓰 | 5-하이드록시트립타민-6 리간드로서의헤테로사이클릴-3-설포닐인다졸 |
-
2002
- 2002-04-19 CA CA002444095A patent/CA2444095A1/en not_active Abandoned
- 2002-04-19 JP JP2002583419A patent/JP4323810B2/ja not_active Expired - Fee Related
- 2002-04-19 MX MXPA03009476A patent/MXPA03009476A/es active IP Right Grant
- 2002-04-19 EP EP02764248A patent/EP1385842A1/en not_active Withdrawn
- 2002-04-19 HU HU0303958A patent/HUP0303958A2/hu unknown
- 2002-04-19 AR ARP020101442A patent/AR035235A1/es not_active Application Discontinuation
- 2002-04-19 EA EA200301142A patent/EA200301142A1/ru unknown
- 2002-04-19 US US10/126,598 patent/US6815456B2/en not_active Expired - Fee Related
- 2002-04-19 BR BR0209056-2A patent/BR0209056A/pt not_active IP Right Cessation
- 2002-04-19 PL PL02367297A patent/PL367297A1/xx unknown
- 2002-04-19 WO PCT/US2002/012415 patent/WO2002085892A1/en active Application Filing
- 2002-04-19 IL IL15844502A patent/IL158445A0/xx unknown
- 2002-04-19 CN CNB028123085A patent/CN1293072C/zh not_active Expired - Fee Related
- 2002-04-19 KR KR10-2003-7013585A patent/KR20030088508A/ko not_active Application Discontinuation
-
2003
- 2003-10-17 EC EC2003004810A patent/ECSP034810A/es unknown
- 2003-10-17 EC EC2003004811A patent/ECSP034811A/es unknown
- 2003-10-17 NO NO20034648A patent/NO20034648L/no not_active Application Discontinuation
- 2003-11-19 ZA ZA200309004A patent/ZA200309004B/en unknown
-
2004
- 2004-09-24 US US10/949,062 patent/US20050065186A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| ECSP034811A (es) | 2003-12-01 |
| BR0209056A (pt) | 2004-08-10 |
| JP4323810B2 (ja) | 2009-09-02 |
| KR20030088508A (ko) | 2003-11-19 |
| ECSP034810A (es) | 2003-12-01 |
| HUP0303958A2 (hu) | 2004-04-28 |
| IL158445A0 (en) | 2004-05-12 |
| CN1293072C (zh) | 2007-01-03 |
| NO20034648L (no) | 2003-11-20 |
| CN1518547A (zh) | 2004-08-04 |
| NO20034648D0 (no) | 2003-10-17 |
| EP1385842A1 (en) | 2004-02-04 |
| CA2444095A1 (en) | 2002-10-31 |
| US20050065186A1 (en) | 2005-03-24 |
| US6815456B2 (en) | 2004-11-09 |
| JP2004526787A (ja) | 2004-09-02 |
| US20030069278A1 (en) | 2003-04-10 |
| PL367297A1 (en) | 2005-02-21 |
| EA200301142A1 (ru) | 2004-02-26 |
| MXPA03009476A (es) | 2004-02-12 |
| AR035235A1 (es) | 2004-05-05 |
| WO2002085892A1 (en) | 2002-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200309004B (en) | Heterocyclylocy-, -thioxy- and -aminobenzazole derivatives as 5-hydroxytryptamine-6 ligands. | |
| JP4208573B2 (ja) | ５−ヒドロキシトリプトアミン−６−リガンドとしての１−アリールまたは１−アルキルスルホニルベンザゾール誘導体 | |
| RU2347780C2 (ru) | Гетероциклил-3-сульфонилиндазолы в качестве лигандов 5-гидрокситриптамина-6 | |
| ES2264994T3 (es) | Compuestos heterociclilalquilindol o -azaindol como ligandos de 5-hidroxitriptamina-6. | |
| ZA200304188B (en) | 1-aryl or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6-ligands. | |
| US20040092526A1 (en) | Heterocyclylindazole and -azaindazole compounds as 5-hydroxytryptamine-6 ligands | |
| MXPA05000649A (es) | Derivados de 1-heterociclilalquil-3-sulfonilindol o indazol como ligandos de 5-hidroxitriptamina-6. | |
| AU2002251811A1 (en) | 1-aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands | |
| AU2002309585B2 (en) | Heterocyclylalkoxy-, -alkylthio- and -alkylaminobenzazole derivatives as 5-hydroxytryptamine-6 ligands | |
| AU2002309585A1 (en) | Heterocyclylalkoxy-, -alkylthio- and -alkylaminobenzazole derivatives as 5-hydroxytryptamine-6 ligands | |
| US20030232843A1 (en) | (1-Substituted-indol-3-yl) alkylidenehydrazinecarboximidamide derivatives as 5-hydroxytryptamine-6 ligands | |
| US7541358B2 (en) | 1-aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands | |
| AU2008203389A1 (en) | Heterocyclyloxy-, -thioxy- and - aminobenzazole derivatives as 5- hydroxytryptamine-6 ligands | |
| AU2002307424A1 (en) | Heterocyclyloxy-, -thioxy- and -aminobenzazole derivatives as 5-hydroxytrypltamine-6 ligands |